Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus LEVORA 0 15 30 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus LEVORA 0 15 30 28.
ENOVID-E vs LEVORA 0.15/30-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Also induces changes in cervical mucus (increasing viscosity) and endometrium (reducing receptivity) to impair sperm penetration and implantation.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
One tablet orally once daily at the same time each day for 28 days (21 active tablets containing 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, followed by 7 placebo tablets).
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Ethinyl estradiol: 13-27 hours (terminal); Levonorgestrel: 11-45 hours (terminal, dose-dependent due to SHBG binding).
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal: ~50% (as glucuronide and sulfate conjugates of ethinyl estradiol and levonorgestrel); Fecal: ~50% (enterohepatic recirculation).
Category C
Category C
Oral Contraceptive
Oral Contraceptive